Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis.

Next Previous
Trial Profile

Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithrombin alfa (Primary)
  • Indications Disseminated intravascular coagulation; Sepsis
  • Focus Therapeutic Use
  • Sponsors LEO Pharma

Most Recent Events

  • 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
  • 28 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database record.
  • 19 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top